Seizure susceptibility of neuropeptide-Y null mutant mice in amygdala kindling and chemical-induced seizure models

Epilepsy Research

Volumn 61, Issue 1-3, 2004, Pages 49-62

  Shannon, Harlan E ^a   Yang, Lijuan ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Amygdala kindling; Kainate induced seizures; Neuropeptide Y; Null mutant mice; Pilocarpine induced seizures; Rapid kindling

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; NEUROPEPTIDE Y;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESISTANCE; EPILEPTOGENESIS; KINDLING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE; WILD TYPE;

AMYGDALA; ANIMALS; ANTICONVULSANTS; CARBAMAZEPINE; CONVULSANTS; ELECTRODES, IMPLANTED; EXCITATORY AMINO ACID AGONISTS; KAINIC ACID; KINDLING, NEUROLOGIC; MICE; MICE, KNOCKOUT; NEUROPEPTIDE Y; PILOCARPINE; PIRACETAM; SEIZURES;

EID: 4644289750     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2004.06.002     Document Type: Article

References (37)

1. Baraban S.C., Hollopeter G., Erickson J.C., Schwartzkroin P.A., Palmiter R.D. Knock-out mice reveal a critical antiepileptic role for neuropeptide Y. J. Neurosci. 17:1997;8927-8936
2. Bijak M. Neuropeptide Y reduces epileptiform discharges and excitatory synaptic transmission in rat frontal cortex in vitro. Neuroscience. 96:2000;487-494
3. Borges K., Gearing M., McDermott D.L., Smith A.B., Almonte A.G., Wainer B.H., Dingledine R. Neuronal and glial pathological changes during epileptogenesis in the mouse pilocarpine model. Exp. Neurol. 182:2003;21-34
4. Bregola G., Fournier A., Zucchini S., Quirion R., Simonato M. Decreased levels of neuropeptide Y5 receptor binding sites in two experimental models of epilepsy. Neuroscience. 98:2000;697-703
5. Cavalheiro E.A. The pilocarpine model of epilepsy. Ital. J. Neurol. Sci. 16:1995;33-37
6. De Prato Primeaux S., Holmes P.V., Martin R.J., Dean R.G., Edwards G.L. Experimentally induced attenuation of neuropeptide-Y gene expression in transgenic mice increases mortality rate following seizures. Neurosci. Lett. 287:2000;61-64
7. El Bahh B., Auvergne R., Lere C., Brana C., La Gal La Salle G., Rougier A. Decreased epileptic susceptibility correlates with neuropeptide Y overexpression in a model of tolerance to excitotoxicity. Br. Res. 894:2001;209-217
8. Erickson J.C., Clegg K.E., Palmiter R.D. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature. 381:1996;415-421
9. Furtinger S., Pirker S., Czech T., Baumgartner C., Ransmayr G., Sperk G. Plasticity of Y1 and Y2 receptors and neuropeptide Y fibers in patients with temporal lobe epilepsy. J. Neuroscience. 21:2001;5804-5812
10. Goddard G.V., McIntyre D.C., Leech C.K. A permanent change I brain function resulting from daily electrical stimulation. Exp. Neurol. 25:1969;295-330
11. Gruber B., Greber S., Rupp E. Differential NPY mRNA expression in granule cells and interneurons of the rat dentate gyrus after kainic acid injection. Hippocampus. 4:1994;474-482
12. Ho M.W.Y., Beck-Sickinger A.G., Colmers W.F. Neuropeptide Y5 receptors reduce synaptic excitation in proximal subiculum, but not epileptiform activity in rat hippocampal slices. J. Neurophysiol. 83:2000;723-734
13. Klapstein G.J., Colmers W.R. On the sites of presynaptic inhibition by neuropeptide Y in rat hippocampus in vitro. Hippocampus. 3:1993;103-111
14. Klapstein G.J., Colmers W.F. Neuropeptide Y suppresses epileptiform activity in rat hippocampus in vitro. J. Neurophysiol. 78:1997;1651-1661
15. Klemp K., Woldbye D.P.D. Repeated inhibitory effects of NPY on hippocampal CA3 seizures and wet dog shakes. Peptides. 22:2001;523-527
16. Kopp J., Nanobashvili A., Kokaia Z., Lindvall O., Hökfelt T. Differential regulation of mRNAs for neuropeptide Y and its receptor subtypes in widespread areas of the rat limbic system during kindling epileptogenesis. Mol. Br. Res. 72:1999;17-29
17. Lurton D., Cavalheiro E.A. Neuropeptide-Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy. Exp. Br. Res. 116:1997;186-190
18. Meldrum B.S. Update on the mechanism of action of antiepileptic drugs. Epilepsia. 37(Suppl 6):1996;S4-S11
19. Palmiter R.D., Erickson J.C., Hollopeter G., Baraban S.C., Schwartz M.W. Life without neuropeptide Y. Recent. Prog. Horm. Res. 53:1998;163-199
20. Racine R.J. Modification of seizure activity by electrical stimulation. Part II. Motor seizures. Electroencephalogr. Clin. Neurophysiol. 32:1972;281-294
21. Reibel S., Benmaamar R., Lê B.T., Larmet Y., Kalra S.P., Marescaux C., Depaulis A. Neuropeptide Y delays hippocampal kindling in the rat. Hippocampus. 13:2003;557-660
22. Rizzi M., Monno A., Samanin R., Sperk G., Vezzani A. Electrical kindling of the hippocampus is associated with functional activation of neuropeptide Y-containing neurons. Eur. J. Neurosci. 5:1993;1534-1538
23. Röder C., Schwarzer C., Vezzani A., Gobbi M., Menni T., Sperk G. Autoradiographic analysis of neuropeptide Y receptor binding sites in the rat hippocampus after kainic acid-induced limbic seizures. Neuroscience. 70:1996;47-55
24. Rogawski M.A., Porter R.J. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol. Rev. 42:1990;223-286
25. Schachter S.C. The next wave of anticonvulsants. Focus on levetiracetam, oxcarbazepine and zonisamide. CNS Drugs. 14:2000;229-249
26. Schwarzer C., Sperk G., Samanin R., Rizzi M., Gariboldi M., Vezzani A. Neruropeptides-immunoreactivity and their mRNA expression in kindling: functional implications for limbic epileptogenesis. Br. Res. Rev. 22:1996;27-50
27. Silva A.J., Simpson E.M., Takahashi J.S., Lipp H.-P., Nakanishi S., Wehner J.M., Giese K.P., Tully T., Abel T., Chapman P.F., et al. Mutant mice and neuroscience: recommendations concerning genetic background. Neuron. 19:2002;755-759
28. Sperk G. Kainic acid seizures in the rat. Prog. Neurobiol. 42:1993;1-32
29. Sperk G., Marksteiner J., Gruber B., Bellmann R., Mahata M., Ortler M. Functional changes in neuropeptide Y-, and somatostatin-containing neurons induced by limbic seizures in the rat. Neuroscience. 50:1992;831-846
30. Tatemoto K. Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc. Natl. Acad. Sci. U.S.A. 79:1982;5485-5489
31. Tschopp M., Statnick M.A., Suter T.M., Heiman M.L. GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein. Endocrinology. 143:2002;558-568
32. Turski L., Ikonomidou C., Turski W.A., Bortolotto Z.A., Cavalheiro E.A. Review: cholinergic mechanisms and epileptogenesis. The seizures induced by pilocarpine: a novel experimental model of intractable epilepsy. Synapse. 3:1989;154-171
33. Vezzani A., Civenni G., Rizzi M., Monno A., Messali S., Samanin R. Enhanced neuropeptide Y release in the hippocampus is associated with chronic seizure susceptibility in kainic acid treated rats. Br. Res. 660:1994;138-143
34. Vezzani A., Michalkiewicz M., Michalkiewicz T., Moneta D., Ravizza T., Richichi C., Aliprandi M., Mule F., Pirona L., Gobbi M., Schwarzer C., Sperk G. Seizure susceptibility and epileptogenesis are decreased in transgenic rats overexpressing neuropeptide Y. Neuroscience. 110:2002;237-243
35. Woldbye D.P.D. Antiepileptic effects of NPY on pentylenetetrazole seizures. Reg. Peptides. 75-76:1998;279-282
36. Woldbye D.P.D., Larsen P.J., Mikkelsen J.D., Klemp K., Madsen T.M., Bolwig T.G. Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors. Nature Med. 3:1997;761-764
37. Woldbye D.P.D., Madsen T.M., Larsen P.J., Mikkelsen J.D., Bolwig T.G. Neuropeptide Y inhibits hippocampal seizures and wet dog shakes. Br. Res. 737:1996;162-168